Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Teva Pharma Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (156)
ARTG (126)
Prescription medicine registration (23)
Australian Public Assessment Report (AusPAR) (7)
Prescription medicine decision summary (3)
Section 14, TGO91 consent (2)
Designation or determination (1)

Date

2024 (120)
2023 (16)
2022 (13)
2021 (68)
2020 (23)
2019 (11)
2018 (6)
2017 (8)
2016 (25)
2015 (9)
2012 (2)
2011 (4)
2010 (1)
2006 (3)
2002 (7)
1995 (2)

Results for "[search-keyword]"

Search

Sponsor content

318 result(s) found, displaying 111 to 120

TE-DASATINIB dasatinib 100 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-DASATINIB dasatinib 20 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
DASATINIB-TEVA dasatinib 100 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-DEFERASIROX deferasirox 360 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-DEFERASIROX deferasirox 180 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-DEFERASIROX deferasirox 90 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
CABAZITAXEL-TEVA cabazitaxel 60 mg/6 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
RASALINE rasagiline (as mesilate) 1 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
DEXMEDETOMIDINE-TEVA dexmedetomidine (as HCl) 200 micrograms/2mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
PALIPERIDONE-TEVA (Teva Pharma Australia Pty Ltd)

22 May 2024

Prescription medicine registration

Active ingredients: paliperidone palmitate.

Pages

First page
Previous page
…
Page 8
Page 9
Page 10
Page 11
Current page 12
Page 13
Page 14
Page 15
Page 16
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.